Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

Investor Relations

Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com

Transfer Agent

Action Stock Transfer
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
F: 801-274-1099
jb@actionstocktransfer.com
www.actionstocktransfer.com